Splenic and hepatic ultrasound and cytology in canine lymphoma: effects of findings on stage migration and assessment of prognosis

Nerschbach, Verena; Eberle, N.; Joetzke, Alexa E; Hoeinghaus, R.; Hungerbuehler, S.; Mischke, R.; Nolte, Ingo; Betz, Daniela Simon

doi:10.1111/vco.12127

Cited by 19 publications

(21 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This led to the inclusion of dogs that had either confirmed ( n = 1) or possible ( n = 5) intra‐abdominal disease. These dogs were included in this study as they lacked peripheral lymphadenopathy, their presenting clinical signs were attributable to the presence of a large mediastinal mass, and questionable prognostic value of hepatic and splenic aspirates in lymphoma staging …”

Section: Discussionmentioning

confidence: 99%

Patient characteristics, prognostic factors and outcome of dogs with high‐grade primary mediastinal lymphoma

Moore

Vernau

Rebhun

et al. 2017

Vet Comparative Oncology

View full text Add to dashboard Cite

The goals of this retrospective study were to determine the patient characteristics of dogs with high-grade primary mediastinal lymphoma and to determine outcome and associated prognostic factors. A total of 42 dogs were identified, in which 36 received treatment and had follow-up information available. The most common clinical signs included lethargy, anorexia and polyuria/polydipsia. Hypercalcemia and pleural effusion were common findings at diagnosis. The phenotype was almost exclusively T-cell, most often in association with lymphoblastic cytomorphology as defined by the World Health Organization (WHO) lymphoma classification scheme. The overall progression-free survival (PFS) and overall survival (OS) were 133 and 183 days, respectively. Treatment with a CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) protocol was associated with an improved PFS (144 days) and OS (194 days) when compared with dogs that received other medical therapies (P = .005 and P = .002, respectively); the absence of pleural effusion at diagnosis was associated with an increased OS but not PFS. These results suggest that while the prognosis for dogs with mediastinal lymphoma is poor, survival may be improved with treatment using a CHOP-based protocol.

show abstract

Section: Discussionmentioning

confidence: 99%

Patient characteristics, prognostic factors and outcome of dogs with high‐grade primary mediastinal lymphoma

Moore

Vernau

Rebhun

et al. 2017

Vet Comparative Oncology

View full text Add to dashboard Cite

show abstract

“…Ultrasonographic changes in homogeneity as well as echogenicity of liver and spleen were considered positive for lymphoma despite published literature 15 …”

Section: Methodsmentioning

confidence: 99%

Are B‐symptoms more reliable prognostic indicators than substage in canine nodal diffuse large B‐cell lymphoma

Skor

Bicanová

Wolfesberger

et al. 2020

Vet Comparative Oncology

View full text Add to dashboard Cite

In humans B‐symptoms refer to systemic symptoms of lymphoma such as fever, weight loss, and night sweats and influence the prognosis of patients. In canine lymphoma, substage B is used to describe any clinical sign observed. Aim of the retrospective study was to compare the prognostic value of substage B with B‐symptoms to predict treatment response and survival in canine nodal diffuse large B‐cell lymphoma. Affected dogs treated with CHOP chemotherapy between 2008 and 2019 were included. B‐symptoms were defined by weight loss greater than 10% of normal weight, fever and the occurrence of unexplained resting tachypnoea substituted human night sweats. Substage B was defined as any symptoms but lymphadenopathy. Fifty‐five cases were included. B‐symptoms were present in 20/55 (36%) and substage B in 40/55 (74%) patients. No significant associations between B‐symptoms or substage B and weight, sex, breed, WHO stage and lymphoma grade were found. Treatment response was negatively associated with both substage B (P = .02) and B‐symptoms (P = .001). B‐symptoms significantly decreased progression free survival (PFS) (95 vs 330 days, P = .001) and lymphoma specific survival (LSS) (160 vs 462 days, P = .001). Data showed that B‐symptoms might be a more reliable prognostic indicator than substage B in canine nodal diffuse large B‐cell lymphoma. Prospective studies assessing B‐symptoms in a larger cohort of patients and in other common lymphoma types are warranted. The abstract was presented at the fourth meeting of the European Canine Lymphoma Network Group in Lugano, 22 June 2019 and published in the proceeding of the meeting on the page 26.

show abstract

“…A number of studies have explored methods to predict outcome in canine lymphoma including refining diagnostic staging methods using cytology and sonography to evaluate the liver and spleen [7], measurement of chemotherapy-induced neutropenia [8], assessment of the relative expression levels of BCL2 and MYC [9], the use of the modified Glasgow Prognostic Score [10]), the immunosignature at diagnosis [11], the assessment of Ki67 and its correlation with mitotic index [12] and flow cytometric characterization of S-phase fraction and ploidy in lymph node aspirates [13]. To date, no useful prognostic indicators have been established that consistently correlate with either the length or lack of remission.…”

Section: Introductionmentioning

confidence: 99%

RNA disruption indicates CHOP therapy efficacy in canine lymphoma

Parissenti

Pritzker²,

Guo

et al. 2019

BMC Vet Res

View full text Add to dashboard Cite

BackgroundAssessment of the efficacy of a multi-agent chemotherapy protocol in which cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) are administered in canine lymphoma is generally performed by physical measurement of lymph node diameter. However, no consistent correlation has been made with prognostic indicators and the length or absence of clinical remission based on lymph node size. RNA disruption measured mid-therapy has been correlated with increased disease-free survival in recent studies of human cancer and was assessed in this study of canine lymphoma patients. Fine needle aspirate samples were taken before treatment and at weeks 3, 6, and 11 of CHOP therapy. RNA was isolated from these samples and assessed using an Agilent Bioanalyzer. RNA disruption assay (RDA) analysis was performed on the data from the resulting electropherograms.ResultsAn increased RNA disruption index (RDI) score was significantly associated with improved progression-free survival.ConclusionsPredicting the risk of early relapse during chemotherapy could benefit veterinary patients by reducing ineffective treatment and could allow veterinary oncologists to switch earlier to a more effective drug regimen.

show abstract

Splenic and hepatic ultrasound and cytology in canine lymphoma: effects of findings on stage migration and assessment of prognosis

Cited by 19 publications

References 48 publications

Patient characteristics, prognostic factors and outcome of dogs with high‐grade primary mediastinal lymphoma

Patient characteristics, prognostic factors and outcome of dogs with high‐grade primary mediastinal lymphoma

Are B‐symptoms more reliable prognostic indicators than substage in canine nodal diffuse large B‐cell lymphoma

RNA disruption indicates CHOP therapy efficacy in canine lymphoma

Contact Info

Product

Resources

About